Literature DB >> 16807454

Role of gemcitabine in ovarian cancer treatment.

D Lorusso1, A Di Stefano, F Fanfani, G Scambia.   

Abstract

Newer agents and combinations are needed in order to improve current results in ovarian cancer treatment. Gemcitabine is a novel agent that has shown promising activity as a single agent in the treatment of platinum-resistant ovarian cancer and a favorable toxicity profile. Because of its clinical and preclinical synergism with platinum analogues, Gemcitabine has been combined with Carboplatin as a convincing approach in the treatment of platinum-sensitive recurrent ovarian cancer patients. Further combination of Gemcitabine and other agents, including paclitaxel, are also feasible and have been actively studied in order to establish the role of Gemcitabine in the management of treated and untreated ovarian cancer patients.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16807454     DOI： 10.1093/annonc/mdj979

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


  22 in total

Review 1.  Drug repurposing for the treatment of COVID-19: Pharmacological aspects and synthetic approaches.

Authors:  Pedro N Batalha; Luana S M Forezi; Carolina G S Lima; Fernanda P Pauli; Fernanda C S Boechat; Maria Cecília B V de Souza; Anna C Cunha; Vitor F Ferreira; Fernando de C da Silva
Journal:  Bioorg Chem       Date:  2020-11-19       Impact factor: 5.275

Review 2.  A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer.

Authors:  Bryan Oronsky; Carolyn M Ray; Alexander I Spira; Jane B Trepel; Corey A Carter; Hope M Cottrill
Journal:  Med Oncol       Date:  2017-04-25       Impact factor: 3.064

3.  The use of treosulfan and gemcitabine in the treatment of platinum-resistant ovarian cancer.

Authors:  S Hilman; P K Koh; S Collins; R Allerton
Journal:  Oncol Lett       Date:  2010-01-01       Impact factor: 2.967

Review 4.  Nanotechnology and Immunotherapy in Ovarian Cancer: Tracing New Landscapes.

Authors:  Bruna Corradetti; Simone Pisano; Robert Steven Conlan; Mauro Ferrari
Journal:  J Pharmacol Exp Ther       Date:  2019-02-08       Impact factor: 4.030

Review 5.  Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.

Authors:  Panagiotis A Konstantinopoulos; Raphael Ceccaldi; Geoffrey I Shapiro; Alan D D'Andrea
Journal:  Cancer Discov       Date:  2015-10-13       Impact factor: 39.397

6.  Nanoscale Coordination Polymers Codeliver Carboplatin and Gemcitabine for Highly Effective Treatment of Platinum-Resistant Ovarian Cancer.

Authors:  Christopher Poon; Xiaopin Duan; Christina Chan; Wenbo Han; Wenbin Lin
Journal:  Mol Pharm       Date:  2016-10-21       Impact factor: 4.939

7.  Defective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes: overcoming transport defects using a nanoparticle approach.

Authors:  Sau Wai Hung; Sean Marrache; Shannon Cummins; Yangzom D Bhutia; Hardik Mody; Shelley B Hooks; Shanta Dhar; Rajgopal Govindarajan
Journal:  Cancer Lett       Date:  2015-01-16       Impact factor: 8.679

8.  Kinetic investigation of the inhibitory effect of gemcitabine on DNA polymerization catalyzed by human mitochondrial DNA polymerase.

Authors:  Jason D Fowler; Jessica A Brown; Kenneth A Johnson; Zucai Suo
Journal:  J Biol Chem       Date:  2008-03-31       Impact factor: 5.157

9.  Gemcitabine and Chlorotoxin Conjugated Iron Oxide Nanoparticles for Glioblastoma Therapy.

Authors:  Qingxin Mu; Guanyou Lin; Victoria K Patton; Kui Wang; Oliver W Press; Miqin Zhang
Journal:  J Mater Chem B       Date:  2015-11-24       Impact factor: 6.331

10.  Combination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with high BCL-2 expression.

Authors:  Foong Ying Wong; Natalia Liem; Chen Xie; Fui Leng Yan; Wing Cheong Wong; Lingzhi Wang; Wei-Peng Yong
Journal:  PLoS One       Date:  2012-12-04       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.